---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Approach and framework"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Approach and framework. Topics: Good-practice framework for budget impact analysis, Structure of a published budget impact model of nadofaragene firadenovec, Potential budget impact method of the ICER review, and Model structures of published cost-effectiveness and cost-per-responder analyses. 4 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics/approach-and-framework"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Approach and framework

<a id="heading-4.2.1"></a>

## 4.2.1 Approach and Framework

<a id="topic-4.2.1-1"></a>

### Budget impact model of cretostimogene grenadenorepvec: approach and framework

No evidence found.

<a id="topic-4.2.1-2"></a>

### Good-practice framework for budget impact analysis

> “The key elements of a BIA include estimating the size of the eligible population, the current mix of treatments and the expected mix after the introduction of the new intervention, the cost of the treatment mixes, and any changes expected in condition-related costs.”
> “Where possible, the BIA calculations should be performed by using a simple cost calculator approach because of its ease of use for budget holders.”

Source: [Sullivan et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24438712/)

> “Finally, the Task Force recommends that the analyst use the simplest design that will generate credible and transparent estimates.”
> “The model should be consistent with that used for the CEA with regard to clinical and economic assumptions.”

Source: [Mauskopf et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17888098/)

<a id="topic-4.2.1-3"></a>

### Structure of a published budget impact model of nadofaragene firadenovec

> “The budget impact was estimated as the differences in total healthcare costs between the following two scenarios: 1) with nadofaragene firadenovec market entry (i.e. a market basket of nadofaragene firadenovec and existing treatment regimens) and 2) without nadofaragene firadenovec market entry (i.e. a market basket of existing treatment regimens only).”
> “Existing treatment regimens for high-risk BCG-unresponsive NMIBC included intravesical treatments – valrubicin, mitomycin C, gemcitabine, BCG + interferon-alpha, and gemcitabine/docetaxel – and systemic therapy with intravenous pembrolizumab.”
> “The total healthcare costs consisted of the following components: drug and drug administration costs, surveillance and disease management costs (including disease-free surveillance costs, recurrence costs, and progression costs), cystectomy costs, and treatment-related adverse events (AE) costs.”
> “Nogapendekin alfa inbakicept-pmln and TAR-200 were not included in the model due to their recent FDA approval and the lack of mature, publicly available market share data.”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="topic-4.2.1-4"></a>

### Potential budget impact method of the ICER review

> “Potential budget impact was defined as the total differential cost of using each new therapy rather than relevant existing therapy for the treated population, calculated as differential health care costs (including drug costs) minus any offsets in these costs from averted health care events.”
> “For 2019-2020, the five-year annualized potential budget impact threshold that should trigger policy actions to manage access and affordability is calculated to be approximately $819 million per year for new drugs.”
> “In this analysis, we assumed that patients eligible for nadofaragene firadenovec or oportuzumab monatox would otherwise have been treated with “usual care” as typified by the hypothetical treatment used in the base case (i.e., no specific bladder cancer-related treatment).”

Source: [ICER Bladder Cancer Final Evidence Report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_Bladder_Cancer_Final_Report_07292022.pdf)

<a id="topic-4.2.1-5"></a>

### Model structures of published cost-effectiveness and cost-per-responder analyses

> “A Markov decision analytic model was created using TreeAge Pro software (TreeAge Software, Inc, Williamstown, Massachusetts).”
> “Each treatment option modelled as a Markov node with health states including surveillance, treatment toxicity, recurrence, progression to MIBC, metastasis, and death (Figure 1).”

Source: [Myers et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13454959/)

> “After treatment initiation with TAR-200 or one of 4 FDA-approved comparator treatments, patients could either 1) attain and sustain CR or 2) not respond; attainment of CR was based on the overall CR rate, and transitions from a state of CR to a state of non-response were evaluated monthly (starting at month 4 for up to 15 months) based on DOR data.”
> “Once in a state of non-response, patients either underwent an RC or received subsequent treatment.”

Source: [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037)

> “We developed a de novo semi-Markov decision analytic model with model structure and inputs informed by key clinical trials, previous economic models, systematic literature reviews, and input from stakeholders (patients, advocacy groups, clinicians, payers, researchers, and manufacturers).”

Source: [Beinfeld et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391138/)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
